Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Adipose tissue stem cells: the great WAT hope.

Cawthorn WP., Scheller EL., MacDougald OA.

Clinical Trial, published in Trends Endocrinol Metab (2012) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Trends Endocrinol Metab (2012)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
22417866
PMCID
PMC3367055
DOI
10.1016/j.tem.2012.01.003
Citations
74

Abstract (original English)

The past decade has witnessed an explosion in research into adipose tissue stem cells (ASCs), facilitated by their ease of isolation from white adipose tissue (WAT) and fueled by their therapeutic potential. Recent developments have extended ASC multipotency to include endodermal and ectodermal cell types, as well as the generation of induced pluripotent stem cells. This expanding multipotency has been paralleled by burgeoning translational applications, ranging from tissue engineering to anti-cancer therapy, that are currently subject to clinical trials. However, this promise is tempered by potential pitfalls, such as tumorigenicity, and is further undermined by lingering uncertainties regarding the precise identity of ASCs. Confronting these issues will be essential if we are to bypass the pitfalls and develop the promises of ASCs.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose Tissue, WhiteAnimalsCell Transformation, NeoplasticGenetic TherapyHumansModels, AnimalParacrine CommunicationPluripotent Stem CellsStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.